Home » Newsletters » BioWorld Science

BioWorld Science

March 4, 2014

View Archived Issues

Overcoming limitations imposed by the BBB using peptide-drug conjugation

Pharmacosmos presents data on iron isomaltoside 1000 for the treatment of iron deficiency and IBD

Abide Therapeutics establishes strategic collaboration with Celgene in inflammation and immunology

The antitumor efficacy of disrupting tumor metabolism by targeting mitochondrial function

Engineered agrin fragment improves disorders involving NMJs dysfunction

Researchers at Merck & Co. design new ROR-gammaT antagonists

Roche designs new XIAP inhibitors for cancer

Genervon's GM-604 receives FDA orphan drug designation for ALS

Former Envoy Therapeutics discloses novel GPR6 receptor ligands

Cumberland Pharmaceuticals acquires drug for hyponatremia

Isis Pharmaceuticals earns milestone for advancing ISIS-TTRRx

Arrowhead cleared to begin phase IIa trial of ARC-520 in Hong Kong

Titan Pharmaceuticals and FDA discuss path forward for Probuphine

Global phase III trial of LR-769 begins in patients with hemophilia A and B

Chugai Pharmaceuticals conducting two phase III trials of SA-237

Transition Therapeutics and Perrigo modify ELND-005 agreement

FDA grants fast track designation to GLYX-13

IntelGenx and RedHill Biopharma respond to FDA Complete Response Letter on VersaFilm NDA

Combination of ABT-263 and GDC-0941 could provide a novel therapeutic regimen for GBM

Intra-Cellular Therapies begins phase I/II trial of ITI-007

Phase II trial of emricasan initiated in NAFLD

Seattle Genetics presents data on Adcetris in Hodgkin's lymphoma

Chimerix presents new data on brincidofovir

Genomind presents data in support of Genecept Assay

Alexion gives update on NICE draft guidance for Soliris in England

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...
IMV-101 shows promise for B-cell malignancies
BioWorld Science
IMV-101 is a new CAR T-cell therapy targeting CD19 developed by Suzhou Immunofoco Biotechnology Co. Ltd. for the potential treatment of B-cell malignancies and...